The biopharmaceutical market has been on a growth curve. India is number three in the Asia Pacific market. Gaurav Kaushik, MD & Director & CEO, Meteoric Biopharmaceuticals shares a perspective on the industry
The biopharmaceutical market has been on a growth curve. India is number three in the Asia Pacific market. Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals shares a perspective on the industry
TATA MD’s OmiSure is the only test approved by the ICMR for RT-PCR detection of the Omicron variant
10 implementation focused initiatives recommended to accelerate policy reforms, standardization of home care delivery services, and improve accessibility and affordability of care in tier II and tier III geographies
It is the generic version of molnupiravir
The test kit is compatible with all standard Real-Time PCR machines with a test run time of 85 minutes. The result turnaround time, including sample collection and RNA extraction, is 130 minutes
Emergency Use Authorisation application request to be submitted following one month required by FDA EUA guidance
The Subject Expert Committee has recommended grant of permission to conduct Phase 3 trials under certain conditions
It will be marketed under the brand name Molunamax
G42 Healthcare and AstraZeneca will work closely together to explore real-world evidence and conduct clinical trials through IROS – the first-of-its-kind Contract Research Organization (CRO) in the UAE
Subscribe To Our Newsletter & Stay Updated
